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Objectives. To estimate and validate a multiattribute
model of the clinical course of Alzheimer disease (AD)
from mild AD to death in a high-quality prospective
cohort study, and to estimate the impact of hypothetical
modifications to AD progression rates on costs associated
with Medicare and Medicaid services. Data and Meth-
ods. The authors estimated sex-specific longitudinal
Grade of Membership (GoM) models for AD patients (103
men, 149 women) in the initial cohort of the Predictors
Study (1989–2001) based on 80 individual measures
obtained every 6 mo for 10 y. These models were repli-
cated for AD patients (106 men, 148 women) in the 2nd
Predictors Study cohort (1997–2007). Model validation
required that the disease-specific transition parameters
be identical for both Predictors Study cohorts. Medicare
costs were estimated from the National Long Term Care
Survey. Results. Sex-specific models were validated
using the 2nd Predictors Study cohort with the GoM
transition parameters constrained to the values esti-
mated for the 1st Predictors Study cohort; 57 to 61 of the
80 individual measures contributed significantly to
the GoM models. Simulated, cost-free interventions in
the rate of progression of AD indicated that large poten-
tial cost offsets could occur for patients at the earliest
stages of AD. Conclusions. AD progression is character-
ized by a small number of parameters governing changes
in large numbers of correlated indicators of AD severity.
The analysis confirmed that the progression of AD repre-
sents a complex multidimensional physiological process
that is similar across different study cohorts. The esti-
mates suggested that there could be large cost offsets to
Medicare and Medicaid from the slowing of AD pro-
gression among patients with mild AD. The methodology
appears generally applicable in AD modeling.
Key words: clinical assessment; outcomes; staging of
dementia. (Med Decis Making 2010;30:625–638)
Modeling the clinical course of Alzheimer dis-ease (AD) is essential for accurate, reliable,
and valid medical decisions for the care and treat-
ment of AD patients and for estimating cost offsets
for proposed medical and pharmaceutical interven-
tions. In addressing these issues, decision makers
have increasingly relied on Markov transition models
to form the core components of their decision
analyses.1
Markov transition models are typically based on 3
assumptions: (A1) that each patient is always in one
of a small number of discrete health states, (A2) that
the transitions from one health state to the next are
independent of the prior states and timings of prior
transitions, and (A3) that the patient population in
each state is homogeneous with respect to the risk of
subsequent transitions. Although such assumptions
are often used in modeling the clinical course of
AD,2 it is recognized that each assumption is only
an approximation that is violated to some degree.3;4
Analyses based on the Cox proportional hazards
model have demonstrated that individual variability
in transition rates is substantial for AD patients,
which violates assumption A3.3;5 Caro and col-
leagues6 dealt with this violation in their Assess-
ment of Health Economics in Alzheimer’s Disease
(AHEAD) model by conducting long-term forecasts
for a 3-state Markov model at the individual-patient
level and by basing transitions on Cox regression
parameters for extrapyramidal signs, psychotic
symptoms, cognitive function, duration of illness,
current age, age at onset of disease, and gender that
A supplemental appendix to this article is published electronically only
at http://mdm.sagepub.com/supplemental.
Web Tables A1–A7 are supplementary tables with detailed statistical tests
and extensive sets of parameter estimates that are provided online in
aWeb-only format for interested readers
Address correspondence to Bruce Kinosian, MD, Ralston House, Rm 226,
3615Chestnut Street,Philadelphia,PA 19104; telephone: (215)573-9623;
fax: (215)573-5566;e-mail:brucek@mail.med.upenn.edu.
DOI: 10.1177/0272989X10363479
CLINICAL HETEROGENEITY AND PREDICTION
MEDICAL DECISION MAKING/NOV–DEC 2010 625
 at COLUMBIA UNIV on January 31, 2011mdm.sagepub.comDownloaded from 
were derived from the Predictors Study.5 This
approach allowed the transitions to depend on the
time in the current state, thereby resolving potential
violations of assumption A2. This model was used
to develop cholinesterase inhibitor guidance for the
National Health Service (United Kingdom),
although Caro and colleagues7 disagreed with this
application of their model.
Although Caro’s specification of the model transi-
tions at the individual patient level resolved some
important violations of the assumptions of the Markov
model, it was not fully satisfactory for generating
long-term forecasts. Two issues remain to be resolved.
First, the Cox regression model implicitly
assumes that the predictors are fixed for individual
patients. Actually, 5 of the 7 predictors (i.e., extrapy-
ramidal signs, psychotic symptoms, cognitive func-
tion, duration of illness, and current age) change
over the course of the disease, with the first 3 being
significant markers of the stage of the disease. These
changes are not addressed by using the Cox regres-
sion model, nor are they addressed elsewhere in
Caro’s model. Adequate resolution of this issue must
also deal with the right-censoring problems typi-
cally encountered in survival analysis.
Second, it is not clear that the Caro model’s use of
3 states—1) not needing full-time care (FTC); 2)
needing FTC, operationalized as nursing home (NH)
institutionalization; and 3) death—are adequate for
characterizing the progression of AD. There are
several options for defining the number and nature
of such states, which can be based on any of several
instruments for the staging of the disease, including
the 7-state Global Deterioration Scale (GDS)8 or the
3-state Clinical Dementia Rating (CDR) scale,9 with
extensions to 4, 5, or 6 states to represent ‘‘question-
able,’’ ‘‘profound,’’ and ‘‘terminal’’ stages.10
Eisdorfer and colleagues11 found that the GDS
incorrectly predicted the timing of psychiatric
symptoms and functional impairments. They recom-
mended separate measures for cognitive, clinical,
and functional status and the development of multi-
dimensional scales.
Bolstering Eisdorfer’s recommendations, Stern
and colleagues12 used longitudinal data from the
Predictors Study to establish that the progression of
AD occurs in 3 dimensions, with different and dis-
tinct nonlinear changes on measures of cognition,
activities of daily living, and instrumental activities
of daily living.
These results invalidate assumption A1 of the Mar-
kov model: It is not true that each patient is always in
one of a small number of discrete health states. The
health states are multidimensional; the multiplicity of
available scales indicates that the states are not dis-
crete. The outcome categories of the multiple attri-
butes used to inform the staging models are discrete,
but they are so numerous that any attempt to represent
them as a single dimensional scale with 3 to 7 stages
necessarily involves substantial simplification and
distortion of the underlying process.
This article takes up Eisdorfer’s challenge to
develop a multidimensional, multiattribute approach
for modeling the progression of AD, thereby resolving
the limitations of the Markov transition model
identified above. The approach responds to Caro and
colleagues’ recent critique of the AHEAD model and
calls for the development of models that ‘‘incorporate
individual patient characteristics and history’’ and
‘‘allow proper handling of competing risks and treat-
ment persistence and compliance.’’7 The approach
also responds to Green’s recent call for ‘‘more appro-
priate methods for the modeling of AD progression’’
using ‘‘multi-attribute health states using a combina-
tion of cognitive function, functional ability, and
behavior and mood.’’13
The fundamental assumption is that the multi-
ple measures of individual patient attributes are
symptoms of AD, not direct measures of the biolog-
ical characteristics of AD itself. The latter are cur-
rently unavailable and hence unobserved; they are
assumed to be the underlying drivers of the disease
and are the missing factors that account for the
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observed symptoms, as evidenced by ongoing
research targeted on discovery of AD biomarkers.14
Moreover, the observed symptoms are assumed to
be only probabilistically determined by the unob-
served biological characteristics of the disease.
This allows patients with the same unobserved
biological characteristics to exhibit different
patterns of symptoms, including occasional rever-
sals in symptoms even as disease progression
continues.
Under this approach, we achieve parsimony and
transparency by using a large number of factors to
identify a low-dimensional process that describes
AD progression. In the remainder of this article, we
describe and report results from such a model.
METHODS
Model
The analyses used a longitudinal form of the
Grade of Membership (GoM) model.15;16 GoM pro-
vides a statistically optimized summarization of
large amounts of data on individual AD patients by
use of a small number of distinct variables that rep-
resent the most salient characteristics of the AD pro-
cess as it develops over time.17;18
Longitudinal GoM is a multidimensional state-
space model that is based on 3 assumptions:
A1. That each patient is always located at some
point (the state vector) in an unobserved low-dimen-
sional continuous bounded state space that accu-
rately represents the biological characteristics of AD
A2. That the changes in the state vector during the
interval from one observation time to the next can
be completely determined by an upper-triangular
transition matrix that characterizes the progres-
sion of AD for that observation interval, with the
axes of the coordinate system ordered by increas-
ing AD severity
A3. That the observed symptoms are random variables
that are conditionally independent, given the state
vector, with the symptom probabilities being func-
tionally dependent on the elements of the state
vector; there is no explicit upper limit to the num-
ber of such symptoms.
To specify this model mathematically, we denote
the categorical data arraya for the observable vari-
ables as fxijtg, where
i ¼ index for I individual AD patients
j ¼ index for J discrete variables in the study
1 ¼ index for Lj symptom
indicators (response levels) within variable j
m ¼ index for M combinations (j, l)
t ¼ index for time since intake examination.
The fundamental equation expresses the proba-
bility of each possible outcome as a time-varying lin-
ear function of the GoM scores:





lmjl ¼ g0iVtlmjl ; ð1Þ
where g0i denotes the transpose of gi, the K-element
column vector of GoM scores for individual i indi-
cating his or her initial location in the postulated
state space of dimensionality D ¼ K  1; the ele-
ments are nonnegative and sum to 1 over the range
of the index k, k = 1, . . . , K . The K elements define
a set of K latent states, classes, or ‘‘pure types.’’ Ut is
the upper-triangular K ×K state-space transition
matrix governing the AD progression over the inter-
val (t; t + 1); the elements in each row are nonnega-
tive and sum to 1. Vt is the K ×K matrix containing
the cumulative product of the t state-space transi-
tion matrices governing the AD progression over the
interval (0, tÞ. By convention, V0 ¼ I, a K × K iden-
tity matrix. lmjl is the K-element column vector of
probabilities for symptom (response) m; the ele-
ments are nonnegative and, for fixed indexes (j, kÞ,
the elements lkmjl sum to 1 over the range of the
index l, l = 1, . . . , Lj.
It follows from assumption A3 that the likelihood



















where yijlt = 1 if xijt = l, and yijlt = 0 if xijt 6¼ l. The
maximum likelihood estimation (MLE) of the para-
meters is described by Stallard.16
For the special case of K = 1, defining a 0-
dimensional (0-D) state space, the right side of equ-
ation 1 is a scalar quantity that is independent of i and
t; the right side of equation 2 is a composite function
formed from the product of J multinomial likelihood
functions with MLE values equal, respectively, to the
aFor simplicity, all continuous variables are assumed to be recoded to
discrete categorical variables prior to the analysis.
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observed relative frequencies of each response to each
of the J variables. The 0-D model is the null model for
statistical model selection.
For any specified value of K , the representation of
the right side of equation 2 as a product over J vari-
ables implies that the J variables are assumed to be
statistically independent. For the 0-D model, this
condition implies marginal independence. For all
other cases, the independence is conditioned on the
state vector (assumption A3).
Equation 2 readily accommodates planned missing
data due to death and various forms of questionnaire
‘‘skip patterns’’ and unplanned randomly missing
data due to dropout and sporadic missing items.16
Erosheva19 used a geometric approach to estab-
lish the connections between the basic nonlon-
gitudinal GoM model and the Rasch model,
demonstrating that the GoM model may be viewed
as a specific form of item response theory (IRT)
model. Erosheva19 further demonstrated that GoM
scores differ from Rasch ability parameters in that
only the former are intrinsic to the response proba-
bility manifold, a characterization that allows GoM
scores to be described as natural measures of latent
traits with certain invariance properties defined by
Ramsay.20 Thus, the 1-D GoM model can describe
multivariate dichotomous categorical data within
an IRT framework with extensions to polytomous
categorical data and to 2-D, 3-D, or higher dimen-
sional models readily implemented.
Selection of the best model from among several
competing (e.g., 1-D, 2-D, 3-D) models is based on
identifying the model with the smallest value of the
Bayesian information criterion (BIC),21;22 computed
for each model as follows:
BIC ¼ 2× lnðLIKÞ þ df × lnðNÞ; ð3Þ
where df is the number of independently adjusted
parameters in the model and N is the effective sam-
ple size.
N can be calculated in 2 ways: 1) N ¼ N*, the
weighted geometric mean number of responses for
the J variables, with the weight for each variable
equal to the df (denoted dfjÞ for the corresponding l
parameters (BIC1), and 2) N ¼ N**, the geometric
mean number of additive terms in the formulas for
the diagonal elements of the df × df Hessian matrix
of the log-likelihood function (BIC2).
N** approximates the dfth root of the ratio of 1) the
determinant of the expected Fisher information
matrix for all observations to 2) the determinant of the
expected Fisher information matrix for 1 observation:
the approximation recommended by Raftery as most
accurate.22 N* is equivalent to the geometric mean
number of additive terms in the formulas for the diag-
onal elements of the partition of the Hessian matrix
corresponding to the l parameters, which excludes
the diagonal elements corresponding to the g and
u parameters; hence, N ¼ N* is expected to be less
accurate.b
For comparison, we also calculated Akaike’s
information criterion (AIC)23 and Bozdogan’s
asymptotically consistent form of AIC (CAIC) using
N ¼ N*.24 For ln(N*) > 2 (i.e., for 8 or more observa-
tions), the following inequality holds: AIC < BIC1 <
CAIC, indicating that model selection decisions
based on BIC1 will be intermediate to those based
on AIC and CAIC.
We hypothesized that the transition matrices {Vt}
governing the changes in the state vectors are funda-
mental parameters of the disease process that are
constant from one patient to the next, within sex,
implying that the transition matrices estimated from
any one database should fit any other. Application
of these matrices to the initial vector of GoM scores,
gi, yields the vectors of time-varying GoM scores,
git, as follows:
g0it ¼ g0iVt: ð4Þ
We tested this hypothesis by applying the BIC selec-
tion procedures to the 2nd Predictors Study cohort
with the transition matrices constrained to the values
estimated for the 1st Predictors Study cohort.
Data
The Predictors Study was specifically designed to
investigate the natural history of AD to develop
improved models for the management of the
disease.25 Case selection was based on the National
Institute of Neurological Disorders and Stroke–
Alzheimer’s Disease and Related Disorders criteria
for probable AD, criteria that were confirmed in up
to 96% of postmortem diagnostic evaluations.26 The
study comprises 2 distinct cohorts, designated Pre-
dictors 1 and Predictors 2, respectively.
Predictors 1 consists of longitudinal follow-up of
103 men and 149 women; Predictors 2 consists of
longitudinal follow-up of 106 men and 148 women.
All cases were determined to have probable AD at
the time of recruitment into the study, with the
bIn fact, BIC1 and BIC2 yielded identical model selection decisions for
all analyses in this article.
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severity of dementia determined to be mild at that
time (generally based on a modified Mini-Mental
Status (mMMS)27 score of 30 or above in Predictors
1 or 16+ on the standard Mini-Mental Status Exami-
nation in Predictors 2).c
The analyses of Predictors 1 were based on the first
21 waves of follow-up, which occurred approximately
every 6 mo over the period 1989 to 2001. The use of
exactly 21 waves was motivated, in part, by the fact
that the total resulting follow-up time was 10 y. Beyond
the 21st wave, the sample sizes became too small.
The analyses of Predictors 2 were based on the
first 16 waves of follow-up, occurring approximately
every 6 mo beginning in 1997, continuing through
early 2007. Beyond the 16th wave (7.5 y follow-up),
the sample sizes became too small.
The longitudinal GoM model was estimated using
79 (women) or 80 (men) variables from Predictors 1
(myocardial infarction was deleted for women due to
no events) and was validated using a closely matched
set of variables from Predictors 2. The variables were
representative of measures likely to be collected in
many AD databases, but they were not an exhaustive
compilation of all variables available in one or the
other of the Predictor Study cohorts. They included
cognition (mMMS, 6 items and total score), functional
capacity (part 1 of the Blessed Dementia Rating Scale
[BDRS],28 11 items and total score; Dependence
Scale,29 13 items, total score, and equivalent institu-
tional care30 levels), behaviors (5 items), psychopatho-
logical symptoms (3 items), motor signs (1 item),
seizures (3 items), vision, cardiovascular disease risk
factors/signs (6 items), alcohol use (4 items), occupa-
tion, citizenship, education, spoken language, demo-
graphic factors, neurologist’s estimation of AD
duration, and 6-mo survival.
The average age (standard deviation) at intake
examination was 71.4 (9.4) y for men and 74.5 (9.0)
y for women in Predictors 1. The corresponding ages
were 75.4 (7.5) y and 77.3 (8.2) y, respectively, in
Predictors 2. The estimated average duration (stan-
dard deviation) of AD at intake was 4.8 (2.7) y for
men and 4.3 (2.4) y for women in Predictors 1. The
corresponding average durations were 4.6 (2.3) y
and 4.3 (2.3) y, respectively, in Predictors 2. On
average, the Predictors 2 cohort was 3 to 4 y older at
intake. The average AD durations in the 2 cohorts
ranged from 4.3 to 4.8 y at intake.
We used the National Long Term Care Survey
(NLTCS) data in supplementary analyses to generate
Medicare cost parameters for each of the GoM pure
types in the NLTCS model in a form that was
matched to each of the GoM pure types in the Pre-
dictors 1 model.
Predictors 2 introduced measures of the cost of
medical care that were not available in Predictors 1
and that were used in the supplementary analyses to
validate the relative cost differentials for Medicare
costs among the GoM pure types in the NLTCS model.
Medicaid NH costs were obtained from Grabowski
et al.31 These costs were assumed to depend only on
the fact of institutionalization, independent of the
individual GoM scores.
All costs were converted to 2007 dollars using the
CPI-U Medical Care series.
RESULTS
Sex-specific 1-D, 2-D, and 3-D models of AD pro-
gression were estimated from Predictors 1 for 103
men and 149 women. Predictors 2 was used in sub-
sequent analyses to validate the results obtained
from Predictors 1. Predictors 2 and the NLTCS were
further used in supplementary analyses to estimate
the costs associated with Medicare-reimbursed med-
ical interventions and Medicaid-reimbursed NH
stays and the cost offsets associated with hypotheti-
cal modifications to AD progression rates.
The 1-D and 3-D models were chosen to reflect
plausible alternative models of AD progression con-
sistent with the review of the literature provided
above. Briefly, standard specifications of both the
Markov transition model and the existing global
assessment scales (e.g., GDS, CDR) imply a 1-D
model of AD progression. Alternatively, analyses by
Eisdorfer, Stern, and others indicated that AD pro-
gression may be better modeled as a 3-D process.11;12
However, these prior reports did not indicate how
this might be done nor how to compare the results of
such a 3-D model with 1-D models.
The analyses were stratified by sex because
prior GoM analyses reported substantial differences
between men and women with respect to the estimated
AD pure types and AD-related care measures.15;18
Predictors 1 Estimation
For each sex-specific model, a total of 79 or 80 vari-
ables (female; male) were employed in estimation.
cSixteen cases in Predictors 1 had an initial modified Mini Mental Sta-
tus score in the range of 21 to 29; 10 cases in Predictors 2 had an ini-
tial Mini-Mental Status Examination score in the range of 9 to 15.
These cases were retained in the analysis because Grade of Member-
ship generates scores for each individual independently.
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Under the Bayesian information criteria (both BIC1
and BIC2), the 3-D models provided better fits for both
sexes to Predictors 1 than the 1-D and 2-D models;
hence, the 3-D models were selected as the best
models.d
Tables 1 and 2 display the sex-specific l para-
meters (i.e., response/symptom probabilities) by
pure type for the 1-D and 3-D models for 10 vari-
ables. Three of the 10 variables were summary
scores for another 30 items not included in the 2
tables: mMMS (6 items), Dependence Scale (13
items), and BDRS (part 1; 11 items).
The remaining 7 variables were selected to dis-
play other important aspects of AD progression.
Residence Status indicates the current place of resi-
dence of the patient; on average (under the heading
‘‘Observed’’ in column 4), 24.4% of men and 33.0%
of women resided in an NH. Equivalent Institutional
Care was derived as an adjunct to the Dependence
Scale; on average, 38.5% of men and 53.6% of
women needed FTC equivalent to that provided in
a health-related facility. These differences are con-
sistent with prior reports that rated FTC risk as
greater than actual NH risk, which justifies keeping
both sets of measures in the model.6 Overall mMMS
Response represents the probability that the mMMS
questions would be attempted at the current exami-
nation; the average attempt rate was 64.2% for men
and 62.5% for women. Moderate Extrapyramidal
Signs indicate the presence/absence of non–drug-
induced motor signs using a Parkinson’s disease rat-
ing scale; 26.0% of men and 30.5% of women exhib-
ited such signs. Delusions and Hallucinations
separately indicate the presence/absence of 2 impor-
tant psychopathological features of AD; 37.3% of
men and 39.7% of women had delusions, but only
13.4% of men and 10.1% of women had hallucina-
tions. Prospective 6-Month Survival represents the
risk of death for individual patients from one exami-
nation to the next; the average death probability was
6.5% for men and 5.5% for women.
Columns 5 to 8 display the parameters, the BICj
statistics, and their rankings (among the full set of
J = 79 or 80 variables) for the 1-D model; columns 9
to 14 display the corresponding parameters, BICj
statistics, and rankings for the 3-D model. The BICj
statistics in columns 8 and 14 are the differences
between the BICj statistics for the 0-D model and the
BICj statistics for the 1-D and 3-D models, respec-
tively. The BICj statistics were computed by restrict-
ing equation 3 to the data for the jth variable with
dfj set equal to the number of free parameters for that
variable; that is, the initial GoM scores and transi-
tion parameters were assumed to be fixed for these
calculations, and Nj was set equal to the correspond-
ing number of observed responses.
Because the BICj statistics account for differ-
ences in sample size and number of parameters, they
can be used to assess the relative influence of the
different variables. Positive values indicate that the
1-D or 3-D model is favored over the 0-D model,
which is true for all comparisons except Hallucina-
tions for the female 1-D model. Each BICj statistic
for the 3-D model is larger than the corresponding
value for the 1-D model, indicating that the 3-D
model is favored over the 1-D model for all 10 vari-
ables. Overall, the BICj statistics were positive for
57 to 61 of the 79 or 80 variables in each sex-specific
1-D or 3-D GoM model.e
The predicted values in columns 5 and 9 are the
marginal probabilities for the 1-D and 3-D models.
They can be compared with the observed values in
column 4 in which the differences were generally in
the range ±0.020, indicating that both models closely
reproduced the observed distributions of outcomes in
the sex-specific study data. For both sexes, the Depen-
dence Scale exhibited the highest rankedBICj statis-
tics for both models. Equivalent Institutional Care
ranked 2nd for 3 of the 4 comparisons, with the
exception being the female comparison of 0-D with
1-D, with BDRS (Part 1) Score moving up to 2nd.
The pure type probabilities in columns 6 to 7 and
10 to 13 are the MLEs of the lmjlparameters for the
1-D and 3-D models, respectively. They can be com-
pared across models and with the observed values
for the 0-D model in column 4. These comparisons
are the key to understanding the substantive mean-
ing of the model.
Consider the pure-type probabilities for the 1-D
model in columns 6 and 7. For both sexes, the esti-
mates for the mild pure type (type I) generally indi-
cated a higher than average (column 4) probability
of a favorable response and a lower than average
probability of an unfavorable response, whereas the
reverse held for the severe pure type (type II).
For Equivalent Institutional Care for men, the
average probability of FTC was 38.5%, which
dSupplementary tables with log-likelihood values from equation 2, cor-
responding Akaike’s information criterion, BIC1, BIC2, and consistent
form of AIC statistics, as well as extensive sets of parameter estimates
are provided online in a Web-only format for interested readers. See
http://mdm.sagepub.com/. eSee Table A2 in the supplementary online material.
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dropped to 0.0% for type I and increased to 90.9%
for type II. For Residence Status, the average proba-
bility of residing in an NH was 24.4% for men,
which dropped to 0.0% for type I and increased to
59.9% for type II.
For the Dependence Scale for men, the average
probability of a rating within levels 4 to 5 was
36.9%, which dropped to 1.0% for type I and
increased to 81.6% for type II. Level 4 included per-
sons who had to be dressed, washed, and groomed;
taken to the toilet regularly; or fed. Level 5 included
persons who had to be turned, moved, or trans-
ferred; assisted with a diaper or catheter; or tube fed.
An important exception to the above generaliza-
tion was the higher than average occurrence of Delu-
sions for type I, with probabilities of 48.9% for men
and 53.7% for women, compared with the respec-
tive average probabilities of 37.3% and 39.7%. This
pattern is consistent with prior reports from the
Predictors Study that the prevalence of delusions
peaked at the 2nd year and then dropped.32 Note,
however, that the 1-D model provides no mecha-
nism for delusions to be predictive of a faster rate of
progression of AD, despite reports of such effects,33
since the rate of progression for all patients is con-
strained to that shown in Web Figures 1 to 3.
Two other observations can be made with respect
to differences between the sex-specific estimates for
type I in the 1-D model. For the Dependence Scale,
the mode occurred at level 2 for men and level 3 for
women, indicating that type I women were more
likely to need supervision. For the mMMS Score, the
mode occurred at 40 to 57 for men and 30 to 39 for
women, indicating that type I women had poorer
cognitive functioning.
The pure-type probabilities for the 3-D model in
columns 10 to 13 indicate, for both sexes, that the
mildest pure type (type I) generally had a higher
than average (column 4) probability of a favorable
response and a lower than average probability of an
unfavorable response, whereas the reverse held for
the severest pure type (type IV).
The response probabilities for types II and III
were less extreme than for types I and IV, consistent
with the assumption that higher numbered pure
types exhibited greater AD severity.
Comparisons with the corresponding results from
the 1-D model in columns 6 and 7 show that the type
I results from the 3-D model were generally more
favorable than the type I results from the 1-D model;
conversely, the type IV results from the 3-D model
were generally less favorable than the type II results
from the 1-D model. Thus, the 3-D model had
a broader range of possible outcomes between the
mildest and severest states than the 1-D model. This
was important because it provided room in the state
space to better represent the individual differences
among individuals who were classified as mild in
the 1-D model.
Trajectories of AD Progression
Web Figure 1 displays the estimated deterioration
in AD health status as a function of time for the 1-D
model, for persons who were initially at the highest
level of health status among the Predictors 1 cohort
(i.e., with a GoM score of 1 on type I). The points on
the plots are the leading diagonal elements of the
Vt matrices, which quantify the cumulative progres-
sion of AD at each 6-mo observation time. Women
deteriorate more rapidly than men, but the timing of
the start and end of the decline in AD health status
is similar. At 5 y, the AD health status score for
women is less than half that for men.
Web Figures 2 and 3 present the individual trajec-
tories of AD progression for the 1-D model, where
each point is the 1st element of the corresponding
GoM score vector, git (see equation 4). The plots in
Web Figures 2 and 3 are bounded above by the sex-
specific plots shown in Web Figure 1. The plots
show that there was substantial heterogeneity in
each study cohort at intake to the study (year 0),
even though all of the participants were determined
to have mild severity of AD at that time. The indi-
vidual trajectories maintain constant proportionality
with respect to each other over the entire duration of
the process. This is the primary constraint imposed
by the 1-D model.
Web Figures 4 and 5 present the individual trajec-
tories of AD progression for the 3-D model, where
each point is the sum of the first 3 elements of the
corresponding GoM score vector, git. The plots show
that there was less heterogeneity in each study
cohort at intake to the study (year 0) in the 3-D than
in the 1-D model (Web Figures 2 and 3). The indi-
vidual trajectories no longer maintain constant pro-
portionality with respect to each other over the
entire duration of the process. Instead, there is sub-
stantial heterogeneity in the rates of progression,
with some individuals reaching the most severe
state in 2.5 y whereas others take as many as 10 years
or more.
Predictors 2 Validation
The Vt matrices estimated from Predictors 1 were
preferable to the Vt matrices estimated from
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Predictors 2 for both sexes for the 3-D model under
the BIC criteria, using the following model forms:
F1. Fix the l and u parameters at the values estimated
from Predictors 1; GoM scores were estimated from
Predictors 2
F2. Fix the u parameters at the values estimated from
Predictors 1; GoM scores and l parameters were
estimated from Predictors 2 (this is the preferred
model form)
F3. All parameters were independently estimated from
Predictors 2
The differences in log-likelihood function values
between Model Forms 2 and 3 were 96.75 for men
and 65.00 for women (90 df each). Based on these
differences, both sets of BIC statistics strongly
favored fixing the transition matrices at the values
estimated from Predictors 1 for both sexes.f
The BIC comparisons between Model Forms 1
and 2 indicated that Form 2 was preferable. This
means that the l parameters from Predictors 1 can-
not be used for Predictors 2. Nonetheless, the BICj
statistics for 32 of 80 variables for men and 44 of 79
variables for women were negative in value, indicat-
ing that the Predictors 1 values would be acceptable
for Predictors 2 in these cases.
Medicare Cost Estimates
Table 3 compares the direct medical care cost
estimates derived from the Predictors 2 data with
the Medicare cost estimates derived from the NLTCS
using the transition parameters from Predictors 1.
Predictors 1 provided no cost data, necessitating the
use of some set of auxiliary procedures to obtain cost
estimates like those in Table 3.
The Predictors 2 estimates with and without use
of the transition parameters from Predictors 1 were
highly correlated (r = 0.99) across the 4 pure types,
supporting the use of the Predictors 1 transitions to
characterize the AD process in the NLTCS cost
estimates.
The NLTCS costs for men were highly correlated
(r = 0.96 each) with the Predictors 2 costs, but the
costs for women were substantially less highly cor-
related (r = 0.76 and 0.80). For men, type I had the
lowest costs among the 4 pure types. For women,
type I had the lowest costs for the Medicare esti-
mates but the 2nd lowest for the direct medical care
estimates obtained from the Predictors 2 data. This
difference accounts for the lower female correlations
between Medicare and Predictors 2 costs.
Applications
Our 2nd objective was to employ the clinical
model to estimate the impact of hypothetical modifi-
cations to progression rates on costs associated with
Medicare and Medicaid services. This was done in
2 steps:
S1. The transition parameters,g probabilities of death
(Tables 1 and 2), and cost estimates (Table 3) were
used to project survival and costs over a 10-y
period corresponding to the 10-y follow-up in Pre-
dictors 1. Table 4 displays the summary results for
the 4 pure types.
S2. The modifications to the AD progression rates
were specified as delays in the start of the deterio-
ration process. A delay was reasonably consistent
with the patterns of deterioration shown in Web
Figures 4 and 5. Two delays were considered:
• a 3-y delay to approximate the largest gaps
between the plots in Web Figures 4 and 5 and
• a 9-mo delay to approximate the size of delays
that could be clinically significant.
Tables 5 and 6 display the simulated interventions
by sex.
The results indicated that large potential offsets
for Medicare costs could occur for patients at the
earliest stages of AD (type I):
• A 3-y delay in initial disease progression produced
10-y cumulative (discounted at 3%) Medicare cost
offsets of $10,015 for men and $11,543 for women
and corresponding average annual offsets of $1526
(men) and $2110 (women).
• A 9-mo delay produced 10-y cost offsets of $2560
(men) and $2173 (women) and annual offsets of $471
(men) and $566 (women).
The results also indicated that large potential off-
sets for Medicaid NH costs could occur for patients
at several stages of AD (types I–III for men; types I–II
for women). For type I:
• A 3-y delay produced 10-y NH cost reductions of
$36,165 (men) and $45,644 (women) and annual
reductions of $4271 (men) and $5873 (women).
fSee Table A5 in the supplementary online material.
gThe transition matrices for the sex-specific 3-D models are reported
in Tables A6 and A7 in the supplementary online material, where they
were combined with the probabilities of death to generate 10-y life
tables for type I. Life tables for the other pure types were computed
similarly.
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Table 4 Sex-Specific Baseline Projections of 10-Y Medicare Costs and Nursing Home (NH) Utilization
















I 8.54 0.99 58,199 6817 40,971 4799
II 6.23 1.70 76,906 12,351 74,679 11,993
III 4.33 2.15 63,752 14,737 100,682 23,275
IV 2.93 2.42 51,949 17,724 119,027 40,610
Women
I 8.38 1.79 65,001 7760 76,587 9143
II 6.05 2.53 66,392 10,970 116,206 19,201
III 4.36 2.87 55,446 12,725 137,806 31,626
IV 4.20 2.61 54,845 13,055 125,584 29,893
Nursing home costs are fixed at the average Medicaid daily rate of $145 in 2007 dollars; costs are discounted at 3% per year.
Table 5 Simulated Cost-Free Intervention Effects on 10-Y Medicare Costs
and Nursing Home (NH) Utilization Rates and Costs (in 2007 Dollars), 3-Dimensional Grade
















I 0.23 –0.29 –2560 –471 –12,145 –1511
II 0.45 –0.15 2612 –440 –7562 –1940
III 0.43 –0.16 3395 –618 –9430 –4086
IV 0.00 0.00 0 0 0 0
36-mo delay
I 0.57 –0.87 –10,015 –1526 –36,165 –4271
II 1.53 –0.74 6940 –1537 –34,640 –6829
III 1.51 –0.66 11,189 –1906 –35,866 –12,177
IV 0.00 0.00 0 0 0 0
Nursing home costs are fixed at the average Medicaid daily rate of $145 in 2007 dollars; costs are discounted at 3% per year.
Table 6 Simulated Cost-Free Intervention Effects on 10-Y Medicare Costs and Nursing
Home (NH) Utilization Rates and Costs (in 2007 Dollars), 3-Dimensional Grade














Cost per Year Lived
9-mo delay
I 0.36 –0.22 –2173 –566 –10,184 –1540
II 0.58 –0.10 3252 –465 –6655 –2676
III 0.00 0.01 –1 –10 330 52
IV 0.00 0.00 0 0 0 0
36-mo delay
I 1.09 –1.03 –11,543 –2,110 –45,644 –5873
II 2.13 –0.53 10,758 –1540 –29,871 –8648
III 0.01 0.02 –10 –27 908 147
IV 0.00 0.00 0 0 0 0
Nursing home costs are fixed at the average Medicaid daily rate of $145 in 2007 dollars; costs are discounted at 3% per year.
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• A 9-mo delay produced 10-y NH cost reductions of
$12,145 (men) and $10,184 (women) and annual
reductions of $1511 (men) and $1540 (women).
The actual federal Medicaid NH cost offsets
would be smaller, because of the following:
• Approximately 50% of AD patients rely on Medicaid
to pay all or part of their NH costs34; the federal gov-
ernment (Centers for Medicare & Medicaid Services)
pays about 60% of these costs, with individual states
paying varying balances in the range of 24% to
50%35 and average costs within individual states
ranging from 30% below to 40% above the national
average cost.31
Thus, no more than 60% of the NH cost reduc-
tions could offset federal Medicaid payments for AD
patients on Medicaid, assuming that all such reduc-
tions would first apply to the Medicaid share of the
NH payments. In this case, the marginal offsets for
all AD patients would be close to 30% of the NH
cost reductions in Tables 5 and 6.
Even with these downward adjustments, the fed-
eral Medicaid NH cost offsets would still be compa-
rable to the Medicare cost offsets (type I).
DISCUSSION AND CONCLUSIONS
The analysis has both substantive and methodo-
logical implications.
Substantively, the analysis provided new esti-
mates of the clinical course of AD that accounted for
initial heterogeneity of the patient population at the
start of follow-up and differential patterns of deteri-
oration of health status over the course of follow-up.
The analysis successfully incorporated multiattri-
bute measures of cognition, function, and behavior in
a low-dimensional representation of AD progression.
The analysis ranked the top predictors in the fol-
lowing order: Dependence Scale, Equivalent Institu-
tional Care, Blessed Dementia Rating Scale (Part 1),
Residence Status, and mMMS.
The estimates suggested that there could be large
cost offsets to Medicare from the slowing of disease
progression among patients with mild AD and sub-
stantial cost offsets to federal Medicaid payments for
NH care from the slowing of disease progression
among patients with both mild and moderate AD.
Methodologically, the longitudinal GoM model
meets Eisdorfer’s11 and Green’s13 criteria that the
model can represent combinations of multiple attri-
butes including measures of cognitive functioning,
functional ability, behavior, and mood and that it
does so in a transparent way.
The approach represents a viable alternative to the
standard Markov transition model, with simpler
assumptions that are more closely satisfied. It differs
from prior applications of the GoM model to cross-
sectional AD data18 in that the longitudinal changes
among individual AD patients are fully integrated
into the model. Rather than representing individual
AD patients as (random) points in a high-dimensional
state space, the approach represents them as (random)
trajectories in a low-dimensional state space.
The use of a low-dimensional state space in GoM
was recommended by Wachter.36 Our innovation
extended Wachter’s recommendation to the low-
dimensional state-space trajectories of longitudinal
GoM with the 3-D dimensionality validated using 2
forms of the Bayesian information criterion and with
the transition parameters validated using a 2nd,
independent data set (Predictors 2). The methodol-
ogy appears applicable to the modeling of existing
AD data sets. It may be sufficiently flexible to incor-
porate future AD progression predictors, such as
biomarkers and brain-imaging technologies.
Our study had several limitations. The 506 cases
in Predictors 1 and 2 were recruited at 3 sites in the
northeastern United States using specific inclusion/
exclusion criteria25 that may influence the generaliz-
ability of the results to other AD patients. Sex differ-
ences in the transition matrices and outcome
probabilities were identified but not modeled fur-
ther. For example, the use of nursing homes and
other paid LTC services was higher for women than
men, in part because of the higher probability of lack
of a spouse to provide care for widowed women.
There are other important fixed variables that are
already in (e.g., demographics) or could be added to
(e.g., APOE genotype) the model that need to be fur-
ther evaluated. The transition matrices in the cur-
rent application were estimated separately for each
observation interval, creating jumps in the trajecto-
ries that could be eliminated by smoothing the tra-
jectories or graduating the transition matrices.
Our study was both exploratory and confirmatory.
We successfully described AD progression as a 3-D
process, validated that description on an independent
data set, and provided strong evidence that AD is not
a 1-D or 2-D process, but we did not prove that AD is
truly a 3-D process. Although the biological mechan-
isms underlying AD progression should be consistent
with a 3-D process, better understanding of those
mechanisms may reveal a substantially more complex
process.
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